Context Therapeutics (CNTX) Cash from Operations (2020 - 2026)

Context Therapeutics has disclosed Cash from Operations across 7 years of filings, most recently posting 11429374.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 11429374.0, down 127.3% year-over-year; the trailing twelve-month figure through Mar 2026 was 32786373.0 (down 115.36% YoY), and the FY2025 annual result was 26385380.0, down 81.26% from the prior year.
• Cash from Operations came in at 11429374.0 for Q1 2026 at Context Therapeutics, down from 8942955.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1933328.0 in Q3 2024 to a low of 11429374.0 in Q1 2026.
• The 5-year median for Cash from Operations is 4631107.0 (2023), against an average of 5115767.06.
• Across the five-year window, Cash from Operations sank 6762.0% in 2022 and jumped 44.14% in 2024, its largest moves.
• Context Therapeutics' Cash from Operations stood at 3929673.0 in 2022, then sank by 83.91% to 7227172.0 in 2023, then jumped by 32.11% to 4906732.0 in 2024, then plunged by 82.26% to 8942955.0 in 2025, then fell by 27.8% to 11429374.0 in 2026.
• The last three Cash from Operations figures came in at 11429374.0 (Q1 2026), 8942955.0 (Q4 2025), and 6578864.0 (Q3 2025), per Business Quant data.